MedTrace Logo

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

NCT05745883 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-04-22

No results posted yet for this study

Summary

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.

Conditions

  • Chronic Kidney Diseases
  • Anemia of Chronic Kidney Disease

Interventions

DRUG

DISC-0974

DISC-0974 is administered subcutaneously

DRUG

Placebo

Placebo is administered subcutaneously

Sponsors & Collaborators

  • Disc Medicine, Inc

    lead INDUSTRY

Principal Investigators

  • Will Savage, MD PhD · Disc Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-04
Primary Completion
2025-10-09
Completion
2026-01-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05745883 on ClinicalTrials.gov